Patient Selection Criteria, Mechanism, Outcomes & Contraindications for Intradiscal PRP

Ideal Patient Profile for Intradiscal PRP

• Chronic discogenic low back pain ≥ 6 months that is the primary pain generator, confirmed by clinical history, physical examination, and concordant imaging findings (MRI showing disc desiccation, high-intensity zone/annular tear, and/or Modic changes)
• Failure of conservative treatment including oral medications, physical therapy, and/or injection therapy (epidural steroid injections, medial branch blocks, etc.)
• Moderate degeneration with preserved disc structure. Complete disc collapse has been consistently excluded from trials as these discs lack sufficient viable cells to respond to biologic stimulation.
• Disc protrusion < 5 mm on MRI or CT — small, contained herniations are acceptable; large extrusions or sequestered fragments are excluded
• 1–3 symptomatic disc levels — most trials treated up to 2–3 levels; multi-level treatment (up to 55% of patients in the Zhang trial) did not appear to diminish outcomes

How Does Intradiscal PRP Work?

• Targets the disc as the primary pain generator — addresses the underlying degenerative process directly rather than only the downstream muscle pain or inflammation of the nerve root
• Overcomes the disc’s poor self-repair capacity — the intervertebral disc is the largest avascular structure in the body, and this lack of blood supply leaves the degenerating disc with very limited ability to heal itself.
• Delivers a supraphysiologic dose of growth factors — injection of concentrated platelets directly into the nucleus pulposus supplies an alphabet soup of growth factors — TGF-β1, PDGF, IGF, VEGF, and EGF where the native healing response is deficient.
• Acts through a dual mechanism:
  • Anabolic effect — stimulates disc cell proliferation and extracellular matrix synthesis.
  • Anti-inflammatory/anti-catabolic effect — downregulates tissue degrading enzymes and pro-inflammatory cytokines that drive both disc breakdown and pain.
• Supported by preclinical data — PRP has been shown in preclinical studies to restore disc height, improve MRI T2 signal, and slow histologic degeneration, while human data continue to evolve.
• Produces durable, disease-modifying relief — a single injection has yielded sustained pain and functional improvement in the majority of appropriately selected patients as far out as 5–9 years, distinguishing it from anti-inflammatory-only approaches.
• Uses the patient’s own blood with no corticosteroid — avoids the systemic effects and cumulative-dose limitations that constrain repeat steroid injections.

What the Research Shows About Results of Intradiscal PRP

• Most patients get meaningful relief. In studies, roughly 55–79% of appropriately selected patients had a clinically important reduction in back pain and improved function within 6 months after a single injection (Schneider et al., The Spine Journal, 2022; Pan et al., Scientific Reports, 2026).
• Relief can last for years. The longest follow-up study found that 71% of patients who responded were still doing well 5 to 9 years after one injection (Cheng et al., 2019). Improvement usually begins around 4–8 weeks and continues over 3–6 months.
• PRP works as well as other options — and lasts longer than steroids. PRP produced results comparable to bone marrow (stem cell) concentrate and was clearly better than placebo (Navani et al., Pain Physician, 2024). Compared with cortisone, steroids may work faster early on, but PRP tends to provide more durable relief at 3–6 months (Akeda et al., 2022).
• A stronger preparation gives better results. Higher platelet concentrations in the PRP (more than 10 times the normal blood level) are linked to greater pain relief, better function, and higher satisfaction (Lutz et al., 2022; Jain et al., 2020).
• It has a strong safety record. Serious complications are rare. The most common effects are a temporary increase in back pain and mild muscle spasms that usually settle within 1–2 weeks. Because PRP is made from your own blood, allergic reactions are very unlikely. Not everyone responds — about 25–30% of patients may need further treatment or surgery.

Contraindications of Intradiscal PRP

• Active local or systemic infection — risk of seeding the disc space; one case of spondylodiscitis with Cutibacterium acnes has been reported after intradiscal PRP
• Hematologic malignancy (active leukemia, lymphoma, myeloma) — PRP composition is altered and there is theoretical risk of disease dissemination to the injection site
• Known bleeding disorder or severe coagulopathy — impairs platelet function and PRP quality
• Severe spinal canal compromise at the levels to be treated
• Pregnancy or breastfeeding

• Active solid tumor or cancer in remission < 5 years
• Immunosuppressive therapy — may alter PRP composition and healing response, recommend case by case evaluation
• Anticoagulation therapy – Can impair platelet function, recommend case by case evaluation
• Inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis) — altered inflammatory milieu may reduce efficacy
• Severe psychological illness or active substance abuse — associated with poor outcomes across all spine interventions
• NSAIDs within 1 week of injection — may impair platelet function and blunt the inflammatory cascade needed for PRP’s mechanism of action

Guideline-Level Recommendations for Intradiscal PRP